Screening-detected breast cancer linked to better outcomes
New research focused on the method of breast cancer detection is reinforcing a message women’s health experts have long understood—that breast cancer screening exams save lives.
Published in the Journal of the American College of Radiology, the study explores the outcomes of over 1,000 women who had the disease detected via routine screening or after undergoing imaging when experiencing symptoms such as a lump, redness or swelling. Breast cancers identified through regular checkups were associated with earlier stage diagnoses, required less aggressive treatment and had substantially better survival rates than those found incidentally or after symptoms developed.
The research team contends their findings could help further refine screening recommendations, ensuring that more women benefit from regular mammography.
“[Method of detection] may help clarify the impact and implementation of breast cancer screening, still a topic of debate. Screening guidelines remain fragmented and continuously evolving,” Babita Panigrahi, MD, with Johns Hopkins University School of Medicine in Baltimore, and colleagues noted. “Major U.S. organizations recommend different starting ages and intervals for average-risk women. The variability in breast cancer screening guidelines reflects differing approaches to weighing the recognized benefits of screening against potential harms and costs, particularly in older women.”
For their work, the group retrospectively evaluated outcomes from over 1,000 women age 40 and older who were diagnosed with breast cancer between 2019 and 2021, with follow-up through July 2026. They classified cancers as either screen-detected or non-screen-detected and examined differences in tumor characteristics, treatment patterns and survival.
Of the women included, 710, or 69.4%, had screen-detected cancers; these patients were significantly more likely to have favorable disease characteristics. More than one quarter (26.3%) had T0 disease compared with 5.4% of women with non-screen-detected cancers. Negative lymph nodes also were substantially more common among screen-detected cancers, at 85.5% versus 59.1%, and 98.6% of screen-detected cancers had no distant metastases compared with 82.4% of non-screen-detected cancers.
Tumor grade followed a similar pattern, with grade 1 disease occurring in 18.6% of screen-detected cancers compared with 7.4% of non-screen-detected cancers. These differences also were reflected in treatment. Women with screen-detected cancers were more likely to undergo lumpectomy (72.1% vs. 50.2%) and less likely to receive neoadjuvant chemotherapy (5.2% vs. 22.5%).
The survival difference was substantial as well. Five-year all-cause survival was 92.9% among women with screen-detected cancers, compared with 73.6% among those whose cases were detected through non-routine methods. After adjusting for other factors, screen detection remained independently associated with a 43% reduction in mortality risk. The survival advantage also was observed among women 75 and older, with screen-detected cancer associated with a 56% lower mortality risk in this group.
The authors suggested that method of detection could provide useful information for cancer registries and potentially help researchers and policymakers better evaluate screening outcomes to develop more effective guidelines.
Read more here.
In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She began covering the medical imaging industry for Innovate Healthcare in 2021.